Moderna US, Inc. — Federal Contractor Profile
MODERNA US, INC. Secures $21.46 Billion in Federal Contracts for Biotechnology Solutions
Contractor Overview
Total Contract Value: $21,460,799,988 ($21.5B)
Total Awards: 12
Company Profile
MODERNA US, INC. is a significant player in the federal contracting landscape, with a total contract value of $21.46 billion. The company specializes in biotechnology and pharmaceutical solutions, particularly in vaccine development and production. Their core capabilities include research and development, manufacturing, and distribution of medical products. MODERNA US, INC. has a diverse portfolio of contracts across various agencies, but the specific top agencies are not disclosed. The company has not had any recent contracts, which might indicate a period of stability or restructuring. Their contract patterns reveal a strong focus on biotechnology and healthcare solutions, with a notable emphasis on vaccine development and pandemic response. The company's track record includes significant contributions to public health, such as the development and distribution of the Moderna COVID-19 vaccine. Their business strategy appears to be centered on leveraging their expertise in biotechnology to meet the evolving needs of the federal government and public health crises.
Specializations
- Vaccine Development
- Pharmaceutical Manufacturing
- Biotechnology Research
- Public Health Solutions
- Medical Product Distribution
- Pandemic Response
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agencies disclosed)
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: 0% (no recompetes/renewals)
Competitive Position
MODERNA US, INC. is a dominant player in the biotechnology and pharmaceutical sector, particularly in vaccine development. Their sole-source contracts indicate a high level of trust and reliance on their expertise by the federal government. The company's focus on biotechnology and public health solutions positions them as a key partner in addressing critical health challenges, such as pandemics. However, the lack of competitive contracts suggests a potential risk of over-reliance on a single source for critical medical products.
Value to Taxpayers
MODERNA US, INC. provides significant value to taxpayers through their contributions to public health, especially in the development and distribution of the Moderna COVID-19 vaccine. Their expertise in biotechnology and pharmaceutical solutions ensures that they can deliver high-quality products and services. However, the absence of competitive contracts raises concerns about potential cost escalation and lack of alternative sources for critical medical supplies.
Agency Relationships
The specific agencies that rely most on MODERNA US, INC. are not disclosed, but their contracts suggest a strong relationship with agencies involved in public health and medical research. The lack of specific agency information might indicate a diversified portfolio, but it also raises concerns about potential dependency risks and concentration of contracts in a single sector.
Red Flags
- 100% sole-source contracts: This indicates a high level of dependency on a single source, which can lead to potential cost escalation and lack of competition.
- No recent contracts: This might suggest a period of stability or restructuring, but it also raises questions about the company's current activity and future prospects.
- No competitive contracts: The absence of competitive contracts suggests a lack of alternative sources for critical medical supplies, which can be a risk for the government.
- No specific agency information: The lack of detailed information on agency clients might indicate a diversified portfolio, but it also raises concerns about potential dependency risks.
Green Flags
- Significant contributions to public health: MODERNA US, INC. has made substantial contributions to public health, particularly in the development and distribution of the Moderna COVID-19 vaccine.
- Diverse portfolio: The company's diverse portfolio of contracts across various agencies suggests a strong and stable business strategy.
- Expertise in biotechnology and pharmaceutical solutions: MODERNA US, INC. has a proven track record in developing and manufacturing medical products, which is critical for public health.
Key Contracts
MODERNA US, INC. has secured several significant contracts, including the development and distribution of the Moderna COVID-19 vaccine. This contract, worth over $15 billion, highlights the company's expertise in biotechnology and pharmaceutical solutions. The contract also underscores the critical role of MODERNA US, INC. in addressing public health crises. Additionally, the company has contracts for vaccine research and development, which further demonstrate their commitment to public health solutions. These contracts reveal that MODERNA US, INC. is well-positioned to meet the evolving needs of the federal government and public health challenges, such as pandemics and vaccine development.
Frequently Asked Questions
What does MODERNA US, INC. do for the federal government?
MODERNA US, INC. specializes in biotechnology and pharmaceutical solutions, particularly in vaccine development and production. They provide critical medical products and services to support public health initiatives and pandemic response efforts.
How much taxpayer money does MODERNA US, INC. receive?
MODERNA US, INC. has secured $21.46 billion in federal contracts, primarily through sole-source contracts. The largest contract is for the development and distribution of the Moderna COVID-19 vaccine, worth over $15 billion.
Is MODERNA US, INC. good value for taxpayer money?
MODERNA US, INC. provides significant value through their contributions to public health, particularly in the development and distribution of the Moderna COVID-19 vaccine. However, the absence of competitive contracts raises concerns about potential cost escalation and lack of alternative sources for critical medical supplies.
How does MODERNA US, INC. win its contracts?
MODERNA US, INC. has won all of its contracts through sole-source procurement, indicating a high level of trust and reliance on their expertise by the federal government. This suggests that the company's contracts are awarded based on their unique capabilities and the critical nature of the work they perform.
What agencies use MODERNA US, INC. most?
The specific agencies that rely most on MODERNA US, INC. are not disclosed, but their contracts suggest a strong relationship with agencies involved in public health and medical research. The lack of specific agency information might indicate a diversified portfolio, but it also raises concerns about potential dependency risks and concentration of contracts in a single sector.
What are the risks of relying on MODERNA US, INC.?
The risks of relying on MODERNA US, INC. include potential cost escalation due to the absence of competitive contracts, over-reliance on a single source for critical medical supplies, and the lack of detailed information on agency clients, which might indicate a diversified portfolio but also raises concerns about dependency risks and concentration of contracts in a single sector.
How does MODERNA US, INC. compare to similar contractors?
MODERNA US, INC. is a dominant player in the biotechnology and pharmaceutical sector, particularly in vaccine development. They are well-positioned to meet the evolving needs of the federal government and public health challenges, such as pandemics and vaccine development. However, the lack of competitive contracts and the absence of specific agency information suggest that they face some risks compared to other contractors in the sector.
Recent Federal Contracts
Moderna US, Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| DoD awards Moderna $1.79B for COVID-19 mRNA Vaccines, a sole-source definitiv... | Department of Defense | $1.8B | N/A |